Abstract

Astroblastomas are rare brain tumours which predominate in children and young adults, and have a controversial claim as a distinct entity, with no established WHO grade. Reports suggest a better outcome than high grade gliomas, though they frequently recur. Recently, they have been described to overlap with a newly-discovered group of tumours described as’high grade neuroepithelial tumour with MN1 alteration’ (CNS HGNET-MN1), defined by global methylation patterns and strongly associated with gene fusions targeting MN1. We have studied a unique case of astroblastoma arising in a 6 year-old girl, with multiple recurrences over a period of 10 years, with the pathognomonic MN1:BEND2 fusion. Exome sequencing allowed for a phylogenetic reconstruction of tumour evolution, which when integrated with clinical, pathological and radiological data provide for a detailed understanding of disease progression, with initial treatment driving tumour dissemination along four distinct trajectories. Infiltration of distant sites was associated with a later genome doubling, whilst there was evidence of convergent evolution of different lesions acquiring distinct alterations targeting NF-κB. These data represent an unusual opportunity to understand the evolutionary history of a highly recurrent childhood brain tumour, and provide novel therapeutic targets for astroblastoma/CNS HGNET-MN1.

Highlights

  • Astroblastomas are rare glial tumours of unknown origin[1]

  • This latter group was associated with gene fusions involving MN1 (22q12.3), usually with BEND2 (Xp22.13), and the alternative partner CXXC5 (5q31.2), and contained 16/23 cases diagnosed as astroblastoma by the originating centres

  • A six-year old girl presented with recurring headaches, and upon magnetic resonance imaging (MRI) a cystic and solid mass within the superior aspect of the left parietal lobe anterior to the central sulcus was observed (Specimen A)

Read more

Summary

Introduction

Astroblastomas are rare glial tumours of unknown origin[1]. These lesions are characterised by the presence of the perivascular pseudorosettes composed of tumour cells with a prominent process extending to a central blood vessel and perivascular hyalinization. CNS-PNETs have recently been resolved by biological subclassification using 450k methylation arrays into either multiple well-known brain tumour pathologies or one of four new molecular entities[8] These novel entities differ in their anatomical location, age at incidence and histological features, and are marked by distinct pathognomonic structural variants, and are described as CNS neuroblastoma with FOXR2 activation (CNS NB-FOXR2), CNS Ewing sarcoma family tumour with CIC alteration (CNS EFT-CIC), CNS high-grade neuroepithelial tumour with BCOR alteration (CNS HGNET-BCOR), and CNS high-grade neuroepithelial tumour with MN1 alteration (CNS HGNET-MN1). We were fortunate to have access to tumour tissue from all 11 surgical interventions from this patient for exome sequencing, which has allowed us the unique opportunity to study the clonal evolution of this novel molecular entity over a long period in the childhood setting, and in response to different treatment strategies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call